IMCR Relative Valuation
IMCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMCR is overvalued; if below, it's undervalued.
Historical Valuation
Immunocore Holdings PLC (IMCR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -45.33. The fair price of Immunocore Holdings PLC (IMCR) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：40.22
Fair
-82.14
PE
1Y
3Y
5Y
Trailing
Forward
-27.53
EV/EBITDA
Immunocore Holdings PLC. (IMCR) has a current EV/EBITDA of -27.53. The 5-year average EV/EBITDA is -57.38. The thresholds are as follows: Strongly Undervalued below -333.54, Undervalued between -333.54 and -195.46, Fairly Valued between 80.70 and -195.46, Overvalued between 80.70 and 218.78, and Strongly Overvalued above 218.78. The current Forward EV/EBITDA of -27.53 falls within the Historic Trend Line -Fairly Valued range.
-39.60
EV/EBIT
Immunocore Holdings PLC. (IMCR) has a current EV/EBIT of -39.60. The 5-year average EV/EBIT is -26.94. The thresholds are as follows: Strongly Undervalued below -72.05, Undervalued between -72.05 and -49.50, Fairly Valued between -4.38 and -49.50, Overvalued between -4.38 and 18.18, and Strongly Overvalued above 18.18. The current Forward EV/EBIT of -39.60 falls within the Historic Trend Line -Fairly Valued range.
4.28
PS
Immunocore Holdings PLC. (IMCR) has a current PS of 4.28. The 5-year average PS is 15.55. The thresholds are as follows: Strongly Undervalued below -15.79, Undervalued between -15.79 and -0.12, Fairly Valued between 31.23 and -0.12, Overvalued between 31.23 and 46.90, and Strongly Overvalued above 46.90. The current Forward PS of 4.28 falls within the Historic Trend Line -Fairly Valued range.
-315.95
P/OCF
Immunocore Holdings PLC. (IMCR) has a current P/OCF of -315.95. The 5-year average P/OCF is -180.05. The thresholds are as follows: Strongly Undervalued below -1434.12, Undervalued between -1434.12 and -807.08, Fairly Valued between 446.98 and -807.08, Overvalued between 446.98 and 1074.01, and Strongly Overvalued above 1074.01. The current Forward P/OCF of -315.95 falls within the Historic Trend Line -Fairly Valued range.
-3645.89
P/FCF
Immunocore Holdings PLC. (IMCR) has a current P/FCF of -3645.89. The 5-year average P/FCF is -232.73. The thresholds are as follows: Strongly Undervalued below -1604.78, Undervalued between -1604.78 and -918.75, Fairly Valued between 453.29 and -918.75, Overvalued between 453.29 and 1139.31, and Strongly Overvalued above 1139.31. The current Forward P/FCF of -3645.89 falls within the Strongly Undervalued range.
Immunocore Holdings PLC (IMCR) has a current Price-to-Book (P/B) ratio of 4.82. Compared to its 3-year average P/B ratio of 6.29 , the current P/B ratio is approximately -23.31% higher. Relative to its 5-year average P/B ratio of 6.18, the current P/B ratio is about -22.04% higher. Immunocore Holdings PLC (IMCR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 0.30%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -2.56% , the current FCF yield is about -100.00% lower.
5.12
P/B
Median3y
6.29
Median5y
6.18
0.15
FCF Yield
Median3y
0.30
Median5y
-2.56
Competitors Valuation Multiple
The average P/S ratio for IMCR's competitors is 0.00, providing a benchmark for relative valuation. Immunocore Holdings PLC Corp (IMCR) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 29.22%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of IMCR increased by 36.32% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -33.11 to -69.09.
The secondary factor is the Revenue Growth, contributed 29.22%to the performance.
Overall, the performance of IMCR in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Immunocore Holdings PLC (IMCR) currently overvalued or undervalued?
What is Immunocore Holdings PLC (IMCR) fair value?
How does IMCR's valuation metrics compare to the industry average?
What is the current P/B ratio for Immunocore Holdings PLC (IMCR) as of Dec 05 2025?
What is the current FCF Yield for Immunocore Holdings PLC (IMCR) as of Dec 05 2025?
What is the current Forward P/E ratio for Immunocore Holdings PLC (IMCR) as of Dec 05 2025?